Oppenheimer Maintains Outperform on Immunovant, Lowers Price Target to $46
Portfolio Pulse from Benzinga Newsdesk
Oppenheimer analyst Leland Gershell maintains an Outperform rating on Immunovant (NASDAQ:IMVT) but lowers the price target from $50 to $46.
June 03, 2024 | 12:26 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
Oppenheimer's analyst Leland Gershell maintains an Outperform rating on Immunovant but lowers the price target from $50 to $46.
The Outperform rating suggests continued confidence in Immunovant's performance, but the lowered price target indicates a slight reduction in expected upside. This mixed signal is likely to result in a neutral short-term impact on the stock price.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 100